This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
2024 Heart Transplant Transplant 
DAIC
MARCH 14, 2025
The Transplant Company recently announced that AlloSureis now commercially available for pediatric heart transplant patients of all ages and patients who have received a simultaneous pancreas-kidney (SPK) transplant. 5 As with other organ transplants, the organs are at risk of rejection.
Becker's Hospital Review - Cardiology
FEBRUARY 11, 2025
In 2024, Boston-based Tufts Medical Center performed 70 adult heart transplants, breaking its 2023 record by nine and setting the New England region record for the second year in a row.
DAIC
JULY 3, 2024
Jon Kobashigawa, MD, of the Smidt Heart Institute at Cedars-Sinai, is an expert in heart transplantation, heart failure, and other complex cardiac conditions. Kobashigawa was instrumental in expanding the Comprehensive Transplant Program at Cedars-Sinai , one of the largest transplant programs in the world. “Dr.
105 
DAIC
FEBRUARY 13, 2024
Pictured Left to Right: Members and students of the McGill Gene Editing Laboratory at The Texas Heart Institute in Houston, Texas: Fansen Meng, PhD, Xiao Li, PhD, James Martin, MD, PhD, Rich Li, PhD (back), Maggie Lim (undergraduate student at Rice University front), Yuka Morikawa, PhD, Ann Bromley.
111 
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4144084-A4144084, November 12, 2024. Despite being a heart transplantation candidate, she declined revascularization and sought alternative treatments for angina, dyspnea, and daily activity limitations.
Becker's Hospital Review - Cardiology
JANUARY 13, 2025
"Vanderbilt Transplant Center sets world record with 174 heart transplants in 2024, including pediatric procedures. Learn more about their achievements and adva
DAIC
MAY 31, 2024
By the end of the study cardiologists performed 10% fewer biopsies in the first year post-transplant and 40% fewer in the second year post-transplant despite an increase in follow-up biopsy rates for dual positives. Hanna , CareDx President and CEO.
105 
DAIC
JANUARY 11, 2024
In organ transplantation, an extended criteria donor is defined as having perceived risk factors linked to poor subsequent outcomes, for example, those with age >55 or ischemic times exceeding 4 hours, which sometimes leads to rejection of the donor organ. utilizing the Paragonix SherpaPak CTS (p=0.022).
111 
Circulation
JANUARY 28, 2024
Circulation, Volume 149, Issue 5 , Page 339-341, January 30, 2024.
Cardiology Update
APRIL 25, 2024
RELIEVE-HF investigators evaluated the efficacy and safety of the V-wave interatrial shunt system in patients with heart failure. The primary endpoint was a composite of all-cause mortality, left ventricular assist device (LVAD)/heart transplantation, HF hospitalizations, worsening HF, and KCCQ score changes. April 6, 2024.
Circulation
OCTOBER 20, 2024
Circulation, Volume 150, Issue 17 , Page 1313-1314, October 22, 2024.
Nature Reviews - Cardiology
JANUARY 22, 2024
Nature Reviews Cardiology, Published online: 23 January 2024; doi:10.1038/s41569-024-00991-6 Heart valve replacement in newborn babies remains an unsolved problem because currently used heart valve implants do not grow. This lack of implant growth mandates serial re-operations until adult-size valve implants can be fitted.
Circulation
MAY 19, 2024
Circulation, Volume 149, Issue 21 , Page 1667-1669, May 21, 2024.
DAIC
FEBRUARY 21, 2024
Getty Images milla1cf Wed, 02/21/2024 - 19:10 February 21, 2024 — Ochsner Children's Hospital , ranked among the top hospitals in the nation for pediatric cardiology and congenital heart surgery, is raising awareness of the need for more pediatric-specific heart devices. For three consecutive years, U.S.
105 
DAIC
APRIL 30, 2024
Study shows that cardiac spheroids, derived from human induced pluripotent stem cells, can be easily transported and injected into damaged areas of the heart to promote its regeneration and recovery of function. Heart attacks typically kill millions of cardiac muscle cells, leaving the heart in a weakened state.
105 
DAIC
APRIL 16, 2024
milla1cf Tue, 04/16/2024 - 12:35 April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional data, including the publication of results of the post-market phase of the BeAT-HF trial in the European Journal of Heart Failure. See more details at TCTMD.
104 
DAIC
MARCH 6, 2024
Food and Drug Adminstration (FDA) has approved DEFINITY (Perflutren Lipid Microsphere) as an ultrasound enhancing agent for use in pediatric patients with suboptimal echocardiograms, including those who have undergone heart transplant, or have Kawasaki disease or a congenital cardiovascular anomaly. 5 Kutty, S., et al (2016).
105 
Cardiology Update
JANUARY 22, 2024
The primary outcome was death from any cause, and the secondary outcome included a composite of death, heart transplantation, or ventricular assist device implantation. At a mean (±SD) follow-up of 40±20 months, CRT showed a significantly lower risk of death or hospitalization due to heart failure.
115 
The American Journal of Cardiology
JULY 24, 2024
Publication date: Available online 23 July 2024 Source: The American Journal of Cardiology Author(s): Giulio Cacioli, Michele Ciabatti, Ernesto Cristiano, Claudia Notari, Ilaria Papisca, Giada Distefano, Giovanni Menafra, Paola Lilla Della Monica, Mariano Antonio Feccia, Amedeo Pergolini, Viviana Maestrini, Fabio Sbaraglia, Federico Ranocchi, Francesco (..)
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4146828-A4146828, November 12, 2024. Heart transplantation remains a vital treatment for end-stage heart failure, yet the scarcity of suitable donor hearts makes the treatment unavailable to many patients in critical need.
40 
DAIC
MAY 15, 2024
milla1cf Wed, 05/15/2024 - 08:50 May 15, 2024 — The U.S. 882 Dates Distributed: March 1, 2021 to present Date Initiated by Firm: March 13, 2024 Device Use The HeartMate 3 Left Ventricular Assist System (LVAS) is used to help the heart pump blood when it is not able to do so effectively on its own.
105 
DAIC
FEBRUARY 22, 2024
The inherited heart condition often goes undiagnosed until it advances to heart failure, which is why it’s important to identify those at risk and begin treatment early. heart failure/heart transplant programs that contributed to the study.
104 
DAIC
APRIL 15, 2024
Image courtesy of Abbott mtaschetta-millane Mon, 04/15/2024 - 09:54 April 15, 2024 — The U.S. This occurs when biological material builds up between certain parts of the device, causing a blockage that makes it harder for the heart to pump blood. Food and Drug Administration ( FDA ) announced A bbott/Thoratec Corp.
105 The American Journal of Cardiology
JULY 6, 2024
Publication date: Available online 6 July 2024 Source: The American Journal of Cardiology Author(s): Jacob Agronin, Meredith Brown, Hannah Calvelli, Huaqing Zhao, Val Rakita, Yoshiya Toyoda, Mohammed Abul Kashem
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4146920-A4146920, November 12, 2024. Cox regression results showed that there is an increased risk of mortality in patients who did not receive transfusions before transplant (p<0.0001).Conclusion:While
40 
DAIC
MARCH 13, 2024
Getty Images milla1cf Wed, 03/13/2024 - 16:49 March 13, 2024 — BioCardia, Inc. , The CMS coverage approval is supported by the scientific rigor of the protocol design and the results from the interim data from the CardiAMP Heart Failure Trial recently presented at the Technology and Heart Failure Therapeutics 2024 annual meeting.
111 
Cardiology Update
APRIL 9, 2024
The American College of Cardiology (ACC) held its 73 rd annual scientific session and expo April 6-8, 2024 in Atlanta, Georgia. Investigators assessed if empagliflozin could lower the risk of hospitalization for heart failure (HF) or death from cardiovascular disease (CVD). April 6, 2024. April 7, 2024. April 7, 2024.
52 
DAIC
MARCH 29, 2024
milla1cf Fri, 03/29/2024 - 08:08 March 29, 2024 — V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American College of Cardiology 's ( ACC ) Annual Scientific Session & Expo taking place April 6-8 in Atlanta. and worldwide," said Neal Eigler, M.D. , CEO of V-Wave.
HeartRhythm
FEBRUARY 29, 2024
In the editorial commentary titled “Is more, “more” when itcomes to pacing in heart transplant patients?” Rod Gimbel published in February 2024 (2024;21;161-162) in Heart Rhythm, the surname of the related article’s first author, Zain Gowani, is incorrectly referred to as Gowali. The author regrets this error.
The British Journal of Cardiology
DECEMBER 3, 2024
A 74-year-old man with a heterotopic heart transplant experienced alternating episodes of sustained native heart ventricular tachycardia and prolonged asystole. These were managed with cardioversion, drug therapy and pacemaker insertion.
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4113494-A4113494, November 12, 2024. End-stage ischemic heart disease necessitates heart transplantation, and emerging cell therapy presents a promising solution to address donor scarcity.
40 
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4146823-A4146823, November 12, 2024. Heart transplant rates were low but increased slightly in 2020 for patients without CHD, with DV and SV CHD patients showing fluctuating rates peaking in 2018 and 2019, then declining in 2020. Patients without CHD were older (mean age 71.5
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4134590-A4134590, November 12, 2024. The association between a lower rate of MAE and EMB persisted in the multivariate model when those with heart transplant who had EMB were compared to those without heart transplant who did not have EMB p=0.001.
DAIC
APRIL 6, 2024
24, in Atlanta, GA. Researchers tracked outcomes in each participant for at least one year and up to two years.
DAIC
APRIL 6, 2024
Stone will present the study, “A Double-blind, Randomized Placebo Procedure-controlled Trial of an Interatrial Shunt in Patients with HfrEF and HfpEF: Principal Results from the RELIEVE-HF Trial,” on Saturday, April 6, 2024, at 9:30 a.m. Researchers tracked outcomes in each participant for at least one year and up to two years.
All About Cardiovascular System and Disorders
FEBRUARY 24, 2024
Heart failure, heart transplantation and death by cardiac causes were more often seen in individuals with biventricular phenotype compared to isolated left or right ventricular phenotype. 2024 Feb 27;83(8):797-807. Phenotypic Expression and Clinical Outcomes in Patients With Arrhythmogenic Cardiomyopathies. 2023.12.015.
Journal of the American Heart Association
DECEMBER 14, 2024
Journal of the American Heart Association, Volume 13, Issue 24 , December 17, 2024. Primary outcomes included changes in Kansas City Medical Optimization score, left ventricular ejection fraction, and cardiovascular eventfree survival (unplanned HF hospitalization, left ventricular assist device /heart transplant, or death).
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4144326-A4144326, November 12, 2024. It has changed the fate of young patients with large tumors who would have otherwise needed heart transplants, offering high suture strength and reducing postoperative complications. During a median follow-up period of 17.4
40 
DAIC
APRIL 8, 2024
milla1cf Mon, 04/08/2024 - 18:07 April 8, 2024 — Implantation of the Impella CP micro-axial flow pump in the hours after a heart attack significantly increased the rate of survival at six months among people suffering cardiogenic shock, according to a study presented at the American College of Cardiology ’s Annual Scientific Session.
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4139383-A4139383, November 12, 2024. Background:Immunosuppressive (IS) therapy is currently used as first-line treatment for heart transplant (HTx) rejection. However, they are not without complications, and less toxic therapies are needed. years, males: 58.4%).
DAIC
JUNE 24, 2024
milla1cf Mon, 06/24/2024 - 20:21 June 24, 2024 — Endotronix, Inc. , a privately held company dedicated to advancing the treatment of heart failure ( HF ) at the intersection of digital health and medtech, today announced Premarket Approval (PMA) from the U.S
109 
Society of Thoracic Surgeons - Research
APRIL 20, 2023
Adult Cardiac Surgery Database Lead Author Title Publication Date Jacob Raphael Red Blood Cell Transfusion and Pulmonary Complications: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis The Annals of Thoracic Surgery January 2024 Joseph Sabik Multi-Arterial versus Single-Arterial Coronary Surgery: Ten Year Follow-up of One Million (..)
52 Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4138589-A4138589, November 12, 2024. All patients were prospectively followed for development of new outcome/cardiac events which included hospitalization for acute HF, CVS-related death, heart transplantation, and also diabetic complications.
European Journal of Heart Failure
DECEMBER 1, 2024
The primary endpoint was survival at 180 days and freedom from implantable cardioverter-defibrillator (ICD), heart transplant/left ventricular assist device (LVAD), or readmission for heart failure. Functional status was assessed with New York Heart Association (NYHA) classification.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content